Abstract
Allogeneic hematopoietic cell transplantation (HCT) is increasingly used for hematologic cancers and utilization is increasing in older patients, ethnic minorities, and for those whom fully human leukocyte antigen (HLA) matched donors are not available. It is also being explored as a salvage option after relapse. The indications and applicability of HCT for specific diseases change over time, especially as non-transplant treatment options and our understanding of disease biology improve. Transplant-related mortality, despite declining over the years, remains an important challenge, while posttransplant relapse has emerged as a major therapeutic focus. General principles, indications, donor selection, and optimal timing of allogeneic HCT for hematologic malignancies in adults and posttransplant outcomes are discussed in this chapter.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
